Coexpression of major histocompatibility complex class II with chemokines and nuclear NFκB p50 in melanoma: a rational for their association with poor prognosis
| Autor: | Olivier Verola, Manuelle Viguier, Frédérique Deshayes, Jessica Lauriol, Dominique Charron, Isabelle Martins, Khaoussou Sylla, Catherine Alcaide-Loridan, Marie-Caroline Dieu-Nosjean, Reem Al-Daccak, Stephanie Ghislin |
|---|---|
| Přispěvatelé: | Institut Jacques Monod (IJM (UMR_7592)), Université Paris Diderot - Paris 7 (UPD7)-Centre National de la Recherche Scientifique (CNRS), Réponses immunes : régulation et développement, Université Paris Diderot - Paris 7 (UPD7)-Institut National de la Santé et de la Recherche Médicale (INSERM), Centre de Recherche des Cordeliers (CRC (UMR_S 872)), Université Pierre et Marie Curie - Paris 6 (UPMC)-Université Paris Descartes - Paris 5 (UPD5)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS), Département de Dermatologie, Université Paris, Service d'anatomo-pathologie [Paris], Université Paris Diderot - Paris 7 (UPD7)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Groupe Hospitalier Saint Louis - Lariboisière - Fernand Widal [Paris], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), CIB-HOG, Groupe Hospitalier Saint Louis - Lariboisière - Fernand Widal [Paris], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), Institut Jacques Monod ( IJM ), Université Paris Diderot - Paris 7 ( UPD7 ) -Centre National de la Recherche Scientifique ( CNRS ), Université Paris Diderot - Paris 7 ( UPD7 ) -Institut National de la Santé et de la Recherche Médicale ( INSERM ), Centre de Recherche des Cordeliers ( CRC (UMR_S 872) ), Université Pierre et Marie Curie - Paris 6 ( UPMC ) -Université Paris Descartes - Paris 5 ( UPD5 ) -Institut National de la Santé et de la Recherche Médicale ( INSERM ) -Centre National de la Recherche Scientifique ( CNRS ), Assistance publique - Hôpitaux de Paris (AP-HP)-Université Paris Diderot - Paris 7 ( UPD7 ) -Groupe Hospitalier Saint Louis - Lariboisière - Fernand Widal [Paris], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Université Paris Diderot - Paris 7 (UPD7)-Groupe Hospitalier Saint Louis - Lariboisière - Fernand Widal [Paris], Assistance publique - Hôpitaux de Paris (AP-HP) (APHP)-Université Paris Diderot - Paris 7 (UPD7)-Groupe Hospitalier Saint Louis - Lariboisière - Fernand Widal [Paris], Assistance publique - Hôpitaux de Paris (AP-HP) (APHP), Assistance publique - Hôpitaux de Paris (AP-HP) (APHP)-Assistance publique - Hôpitaux de Paris (AP-HP) (APHP) |
| Rok vydání: | 2009 |
| Předmět: |
Male
MESH: NF-kappa B p50 Subunit Cancer Research Chemokine Skin Neoplasms MESH : Aged MESH: NF-kappa B MESH : Neoplasm Invasiveness [ SDV.CAN ] Life Sciences [q-bio]/Cancer MESH: Aged 80 and over 0302 clinical medicine [ SDV.IMM ] Life Sciences [q-bio]/Immunology MESH : Female Extracellular Signal-Regulated MAP Kinases Melanoma MESH: Extracellular Signal-Regulated MAP Kinases Aged 80 and over MESH: Aged Regulation of gene expression MESH : Trans-Activators 0303 health sciences MESH : Prognosis MESH: Middle Aged Kinase NF-kappa B Nuclear Proteins MESH: Gene Expression Regulation Neoplastic MESH : Adult Middle Aged Prognosis MESH: Chemokines MESH : Extracellular Signal-Regulated MAP Kinases Gene Expression Regulation Neoplastic Oncology MESH : NF-kappa B 030220 oncology & carcinogenesis Disease Progression [SDV.IMM]Life Sciences [q-bio]/Immunology Female MESH: Disease Progression Chemokines Matrix Metalloproteinase 1 Adult Proto-Oncogene Proteins B-raf MESH: Cell Line Tumor P50 MESH : Gene Expression Regulation Neoplastic MESH: Melanoma MESH: Trans-Activators MESH : Male MESH : Melanoma [SDV.CAN]Life Sciences [q-bio]/Cancer Dermatology Biology MESH: Prognosis 03 medical and health sciences MESH : HLA-DR Antigens Cell Line Tumor Extracellular medicine Humans MESH : Middle Aged MESH : Chemokines Neoplasm Invasiveness MESH : Aged 80 and over Protein kinase A MESH : Proto-Oncogene Proteins B-raf Aged 030304 developmental biology MESH: Proto-Oncogene Proteins B-raf MESH: Humans MESH : Matrix Metalloproteinase 1 MESH : Cell Line Tumor MESH: Skin Neoplasms MESH : Humans MESH : Skin Neoplasms MESH: Biological Markers MESH : Nuclear Proteins NF-kappa B p50 Subunit MESH: Adult MESH : Disease Progression HLA-DR Antigens MESH: Neoplasm Invasiveness MESH: HLA-DR Antigens medicine.disease MESH: Male MESH : Biological Markers MESH: Matrix Metalloproteinase 1 MESH : NF-kappa B p50 Subunit Tumor progression Immunology Trans-Activators biology.protein MESH: Nuclear Proteins MESH: Female Biomarkers |
| Zdroj: | Melanoma Research Melanoma Research, Lippincott, Williams & Wilkins, 2009, 19 (4), pp.226-37. ⟨10.1097/CMR.0b013e32832e0bc3⟩ Melanoma Research, Lippincott, Williams & Wilkins, 2009, 19 (4), pp.226-37. 〈10.1097/CMR.0b013e32832e0bc3〉 Melanoma Research, 2009, 19 (4), pp.226-37. ⟨10.1097/CMR.0b013e32832e0bc3⟩ |
| ISSN: | 0960-8931 |
| Popis: | International audience; The constitutive expression of major histocompatibility complex class II (MHC II) molecules in melanoma is highly unusual and has been associated with unfavorable clinical outcome and higher metastatic dissemination. This association remains poorly understood and therefore, in this study we looked to whether it is caused by intracellular events that promote tumor progression. We previously reported that MHC II expression in melanoma cells requires active mitogen-activated protein kinase/extracellular signal-related kinase. However, our comparative and molecular analyses of a panel of melanoma cell lines herein provide clear evidence that mitogen-activated protein kinase/extracellular signal-related kinase is not sufficient for HLA-DR expression. We found that the expression of HLA-DR in these tumors rather coincides with the expression of CXCL-1 and CXCL-8 chemokines, both known to be expressed in tumors that invade early and are related to invasive stages of melanoma. The expression of HLA-DR also nicely paralleled that of the nuclear NFkappaB p50 subunit, regulating the expression of these chemokines in melanoma and previously correlated with poor prognosis of melanoma patients, although we provide evidence that NFkappaB is not directly regulating MHC II expression level. The molecular basis for class II transactivator and HLA-DR expression in melanoma therefore remains unsolved, but our findings linking together the expression of HLA-DR, of chemokines involved in invasiveness, and of nuclear NFkappaB p50 strongly support the content that MHC II may be a marker of invasive primary melanoma, and could explain the long-standing association of MHC II expression with overall poor prognosis and unfavorable clinical outcome. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|